ALGOTHERAPEUTIX
AlgoTx creates solutions to help patients suffering from difficult-to-treat conditions. The organization accomplishes this by emphasizing conditions with no proven or licensed therapy and adapting treatment to the very particular needs of the people afflicted. ATX01's admission into Phase 2 in Chemotherapy-Induced Peripheral Neuropathy has been approved by the FDA. In the meanwhile, AlgoTx is investigating its potential in erythromelalgia, a rare and painful condition.
ALGOTHERAPEUTIX
Social Links:
Industry:
Biotechnology Information Technology Pharmaceutical
Founded:
2018-01-01
Address:
Suresnes, Ile-de-France, France
Country:
France
Website Url:
http://www.algotx.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
37.41 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF SSL By Default Euro Apple Mobile Web Clips Icon Google Font API WordPress LetsEncrypt DNSSEC
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Eidos Therapeutics
Eidos Therapeutics is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients.
NMD Pharma
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Current Advisors List
Current Employees Featured
Founder
Investors List
Omnes Capital
Omnes Capital investment in Series B - AlgoTherapeutix
Bpifrance
Bpifrance investment in Series B - AlgoTherapeutix
InnoBio Fund
InnoBio Fund investment in Series B - AlgoTherapeutix
Bpifrance
Bpifrance investment in Grant - AlgoTherapeutix
UI Investissement
UI Investissement investment in Series B - AlgoTherapeutix
Turenne Capital
Turenne Capital investment in Series B - AlgoTherapeutix
Bpifrance
Bpifrance investment in Series A - AlgoTherapeutix
Omnes Capital
Omnes Capital investment in Series A - AlgoTherapeutix
Bpifrance
Bpifrance investment in Seed Round - AlgoTherapeutix
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-08 | AlgoTherapeutix appoints Prof Jens Ellrich Chief Medical Officer |
Official Site Inspections
http://www.algotx.com Semrush global rank: 7.13 M Semrush visits lastest month: 895
- Host name: cluster021.hosting.ovh.net
- IP address: 188.165.53.185
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "AlgoTherapeutix"
About us - AlgoTx
AlgoTherapeutix (AlgoTx) is a clinical stage biotechnology company developing targeted, first in class therapeutics for peripheral neuropathic pain. Our lead asset, ATX01, is a non-opioid, locally acting agent. It targets the signaling …See details»
AlgoTherapeutix - Crunchbase Company Profile & Funding
AlgoTx creates solutions to help patients suffering from difficult-to-treat conditions. The organization accomplishes this by emphasizing conditions with no proven or licensed therapy …See details»
AlgoTx - LinkedIn
AlgoTx is a clinical stage biotechnology company developing targeted, first in class therapeutics for peripheral neuropathic pain. Non-opioid, locally acting ATX01 is designed to treat the pain of ...See details»
AlgoTx Company Profile 2024: Valuation, Funding & Investors
AlgoTx General Information Description. Operator of a biotechnology company intended to develop topical treatments for complex pain. The company directly targets the damaged nerve …See details»
2020 – AlgoTx
SURESNES, France- June 8th 2020 -(BUSINESS WIRE)–European biotech AlgoTx, an innovator in complex pain therapy, today announces the U.S. Food and Drug Administration (FDA) has …See details»
AlgoTx: Contact Details and Business Profile - RocketReach
AlgoTx raised a Series B round of EUR 20 million in 2022 and has raised EUR 35 million to date. AlgoTx has a consortium of investors including Relyens Innovation Santé / Turenne Capital, …See details»
AlgoTx Company Profile - Office Locations, Competitors, Revenue …
AlgoTx has 5 employees across 2 locations and $22.49 m in total funding,. See insights on AlgoTx including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
AlgoTx - Company Profile - Tracxn
Nov 27, 2024 AlgoTx. has raised a total funding of $39.3M over 4 rounds. Its first funding round was on Jun 01, 2018. What are the most recent funding rounds of AlgoTx? Its latest funding …See details»
AlgoTherapeutix Company Information - Funding, Investors, and …
Website: https://algotx.com; Company size: 1 - 11 employees Headquarters: Paris, France Founded: 2018 Social accounts: Linkedin; Similar startup. Mistral AI Seedtable Score 78. …See details»
Series B - AlgoTherapeutix - 2023-03-14 - Crunchbase
Organization Name . AlgoTherapeutix . Announced Date Mar 14, 2023; Funding Type Series B; Funding Stage Early Stage Venture; Money Raised . €20M. Lead Investors. ... Business Wire …See details»
Stephane Thiroloix - AlgoTx | BIO-Europe Spring Speaker
AlgoTx was awarded the 2023 ESG HealthTech Trophy in recognition of the biotech’s early commitment to ESG initiatives. Stephane graduated in 1986 from the HEC business school. …See details»
AlgoTx - Overview, News & Similar companies | ZoomInfo.com
May 31, 2022 AlgoTx has announced that Jens Ellrich has joined the organization as Chief Medical Officer. ... and Bpifrance through its Innobio 2 fund and Omnes Capital. AlgoTx also …See details»
Contact - AlgoTx
Headquarters 49 rue des Nouvelles 92150 Suresnes France. Operations Tour Sequana 82 rue Henry Farman 92130 Issy-Les-Moulineaux FranceSee details»
AlgoTx unveils plans for Phase II trial for rare chronic condition
Mar 29, 2023 According to the National Organization for Rare Disorders (NORD), ... Stéphane Thiroloix, CEO of AlgoTx . Alongside erythromelalgia, the company is testing ATX01 in a …See details»
AlgoTx | BIO-Europe - Informa Connect
There is no approved treatment for EM. Both studies will read out in 2024. AlgoTx raised 35 M€ to date, including a 19 M€ Series B in March 2023 led by a syndicate of 4 European funds. …See details»
AlgoTx Raises €20 Million in Series B | News & Events | Goodwin
Mar 3, 2023 AlgoTx develops novel solutions for complex pain. Their lead program, ATX01, targets highly prevalent Chemotherapy-Induced Peripheral Neuropathy and the orphan …See details»
Press releases - AlgoTx
Disclaimer. © algotx® all rights reserved 2024See details»
Science - AlgoTx
AlgoTx was initially inspired to develop ATX01 by the exploratory work of a few physicians, which was ultimately published in two prospective studies of 44 (2019 7) and 25 (2021 5) patients at …See details»
Events - AlgoTx
Nov 4, 2024 disclaimer. © algotx® all rights reserved 2024See details»